Impact of Financial Incentives
- Conditions
- Human Papilloma Virus
- Registration Number
- NCT05744960
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Brief Summary
This trial will look at the impact of clinic-level financial incentives to improve provider communication and increase HPV vaccine uptake. Some clinics will receive communication training. Other clinics will receive the same training and a clinic-level financial incentive program with a monthly data feedback report to increase HPV vaccine uptake.
- Detailed Description
The researchers will conduct a cluster randomized control trial. This trial will look at the impact of clinic-level financial incentives to improve provider communication and increase HPV vaccine uptake. The recruitment goal for the trial is 34 clinics in healthcare systems, including 9 rural-serving clinics. The researchers will randomize clinics using simple randomization (1:1). Some clinics will receive communication training. Other clinics will receive the same training and a clinic-level financial incentive program with a monthly data feedback report to increase HPV vaccine uptake. The researchers will use medical record data to compare changes in HPV vaccination among children ages 9-12. Clinics will be followed for 24 months. The study will engage clinical staff. Researchers will not have direct contact with children or their families.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 34
Clinics are eligible if they are a pediatric or family medicine clinic in North Carolina that in the past year had:
- less than 72% HPV vaccine initiation rate,
- greater than or equal to 50 patients ages 9-12
- greater than or equal to 2 HPV vaccine providers
- no clinic or provider-level financial incentive programs to increase system, clinic, or provider HPV vaccination rates among patients aged 9-12 in the past two years, and
- no HPV vaccine provider communication trainings in the past six months.
Children's medical records will be eligible to be included in the dataset if children:
- are between the ages of 9-12 years at baseline and
- are attributed to a participating clinic at 12- or 24-month follow-up.
Clinics are excluded if they:
- do not provide HPV vaccine to children ages 9-12
- have a specialty other than pediatrics or family medicine
- had an HPV vaccine-specific financial incentive program in the past two years
- had a formal HPV vaccine communication training in the past 6 months
- had an HPV initiation rate greater than 72$
- had fewer than 49 patients aged 9-12
- had 1 or fewer HPV vaccine providers
Children's medical records will not be eligible to be included in the dataset if children:
- are not between the ages of 9-12 years at baseline
- are not attributed to a participating clinic at 12- or 24-month follow-up
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method HPV vaccination (≥1 dose), 9-12 year olds from baseline to 12 months Proportion of unvaccinated children who initiate the HPV vaccine series between baseline and 12-month follow-up, among those who were ages 9-12 at baseline.
- Secondary Outcome Measures
Name Time Method HPV vaccination (≥1 dose), 9-12 year olds from 13 months to 24 months Proportion of unvaccinated children who initiate the HPV vaccine series between 13- and 24-month follow-up, among those who were ages 9-12 at 13 months.
HPV vaccination (≥2 doses), 9-12 year olds from 13 months to 24 months Proportion of unvaccinated children who complete the HPV vaccine series between 13- and 24-month follow-up, among those who were ages 9-12 at 13 months.
Trial Locations
- Locations (1)
University of North Carolina at Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
University of North Carolina at Chapel Hill🇺🇸Chapel Hill, North Carolina, United StatesKathryn R Brignole, MScContact919-966-3036brignolk@ad.unc.edu